인간 유전자 시퀀싱 시장 : 용도별, 기술별, 워크플로우별, 제품별 및 국가별 전략, 동향, 예측 - 경영진용 가이드, 컨설턴트용 가이드 및 인공지능(AI)의 영향(2026-2030년)

Market Overview:

Human gene sequencing refers to a group of technologies used to determine the precise order of nucleotides within DNA. These technologies enable identification of genetic variations associated with disease risk, treatment response, and biological function. Since completion of the Human Genome Project in 2003, advances in sequencing technologies have dramatically reduced cost and improved throughput, transforming gene sequencing from a specialized research activity into a core tool for clinical diagnostics, pharmaceutical development, and biomedical research.

The global human gene sequencing market has expanded rapidly as applications in precision medicine, oncology, rare disease diagnostics, reproductive health screening, and pharmacogenomics have grown. The market is over USD 11.5 Billion in 2025 and growing to 21.4 Billion by 2030. This represents a growth rate of 13.1%. Next-generation sequencing (NGS) represents the largest technology segments due to its ability to sequence millions of DNA fragments simultaneously.

Human gene sequencing technologies are increasingly integrated into clinical decision-making processes. Sequencing-based diagnostics enable identification of genetic mutations associated with cancer, inherited diseases, and treatment response. As healthcare systems adopt precision medicine approaches, gene sequencing is becoming an essential component of modern clinical practice.

Technology Evolution

Gene sequencing technologies have evolved significantly over the past two decades. First-generation sequencing methods, such as Sanger sequencing, were widely used for early genomic research but were limited by relatively low throughput and high cost per sample.

Next-generation sequencing technologies have largely replaced first-generation methods for most applications. NGS platforms allow simultaneous sequencing of millions of DNA fragments, enabling comprehensive genomic analysis at significantly lower cost per base. NGS technologies support a range of applications including whole genome sequencing (WGS), whole exome sequencing (WES), targeted gene panels, and transcriptome sequencing.

Third-generation sequencing technologies, including single-molecule and long-read sequencing methods, are gaining increasing attention due to their ability to detect structural variants and complex genomic regions that may be difficult to analyze using short-read methods. Long-read sequencing technologies provide improved characterization of repetitive sequences and structural rearrangements.

Sequencing workflows typically involve sample preparation, library construction, sequencing reactions, and bioinformatics analysis. Advances in automation and cloud-based bioinformatics tools have improved workflow efficiency and data interpretation capabilities.

Key Applications

Human gene sequencing is used across a wide range of clinical and research applications.

Oncology represents one of the largest application areas. Sequencing technologies are used to identify genetic mutations associated with cancer development and progression. Molecular profiling enables identification of actionable mutations that can guide targeted therapy selection.

Rare disease diagnostics represent another important application area. Many rare diseases have genetic origins, and sequencing technologies can help identify pathogenic variants responsible for disease symptoms.

Non-invasive prenatal testing (NIPT) uses sequencing of cell-free fetal DNA circulating in maternal blood to detect chromosomal abnormalities such as trisomy 21.

Pharmacogenomics uses genetic information to predict patient response to drugs and guide dosing decisions.

Infectious disease sequencing supports surveillance of viral and bacterial pathogens and monitoring of emerging variants.

Research applications include gene discovery, population genomics, evolutionary biology, and biomarker identification.

Market Drivers

Several factors are driving growth in the human gene sequencing market.

• Increasing adoption of precision medicine approaches is creating demand for genomic information that supports personalized treatment decisions.
• Growth in oncology drug development is increasing use of sequencing technologies to identify therapeutic targets.
• Large population genomics initiatives are generating demand for high-throughput sequencing technologies.
• Technological advances are reducing sequencing costs and improving accessibility.
• Expansion of clinical guidelines incorporating genomic testing is supporting broader adoption.
• Increasing availability of bioinformatics tools is improving interpretation of genomic data.

Market Segmentation

The human gene sequencing market can be segmented by technology type, application, end user, and geographic region.

By technology, next-generation sequencing represents the dominant segment due to high throughput capabilities. Whole genome sequencing, whole exome sequencing, and targeted gene panels represent important application formats.

By application, NIPT and Oncology represents the largest segments.

North America represents the largest geographic market due to strong research infrastructure and high adoption of genomic medicine. Europe and Asia-Pacific markets are also expanding as governments invest in genomic research initiatives.

Competitive Landscape

The human gene sequencing market includes instrument manufacturers, reagent suppliers, sequencing service providers, and bioinformatics companies.

Competition is driven by sequencing accuracy, throughput, cost efficiency, and data analysis capabilities.

Companies are increasingly offering integrated solutions combining sequencing instruments, consumables, and bioinformatics software.

Strategic partnerships between sequencing technology providers and pharmaceutical companies are common, particularly in biomarker discovery and clinical trial applications.

Data interpretation capabilities and access to genomic databases are becoming important competitive differentiators.

Barriers to entry remain significant due to capital requirements, technical expertise, and regulatory considerations.

Future Outlook

The human gene sequencing market is expected to continue expanding as sequencing technologies become more integrated into healthcare systems and research programs.

Declining sequencing costs are expected to increase adoption of whole genome sequencing.

Advances in artificial intelligence and bioinformatics are expected to improve interpretation of genomic data.

Population genomics initiatives may increase use of sequencing technologies in preventive medicine.

Integration of genomic data into electronic health records may support personalized treatment approaches.

Emerging long-read sequencing technologies may improve detection of structural variants and complex genomic features.

Overall, human gene sequencing represents a foundational technology supporting precision medicine, biomedical research, and drug development. Continued technological innovation and expanding clinical applications are expected to drive long-term market growth.

Table of Contents

1 Market Guides

• 1.1 Human Gene Sequencing Markets - Strategic Situation Analysis
  • 1.1.1 Strategic Importance in Precision Medicine
  • 1.1.2 Cost Reduction and Economic Pressures
  • 1.1.3 Technology Innovation and Platform Competition
  • 1.1.4 Data Analysis and Bioinformatics Challenges
  • 1.1.5 Regulatory and Ethical Considerations
  • 1.1.6 Reimbursement and Clinical Adoption Barriers
  • 1.1.7 Competitive Landscape and Industry Structure
  • 1.1.8 Expansion of Clinical Applications
  • 1.1.9 Outlook and Strategic Implications
• 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
• 1.3 Guide for Management Consultants and Investment Advisors
• 1.4 Impact of Artificial Intelligence on Gene Sequencing Market

2 Introduction and Market Definition

• 2.1 Gene Sequencing Definition In This Report
  • 2.1.1 Gene Sequencing
  • 2.1.2 Hereditary
  • 2.1.3 Non Invasive Prenatal Testing
  • 2.1.4 Oncology
  • 2.1.5 Psychology
  • 2.1.6 WGES
  • 2.1.7 Pharmacogenomic
  • 2.1.8 Direct to Consumer
  • 2.1.9 Research
  • 2.1.10 Other
• 2.2 The Genomics Revolution
• 2.3 Market Definition
  • 2.3.1 Revenue Market Size
• 2.4 Methodology
  • 2.4.1 Methodology
  • 2.4.2 Sources
  • 2.4.3 Authors
• 2.5 Perspective: Healthcare and the IVD Industry
  • 2.5.1 Global Healthcare Spending
  • 2.5.2 Spending on Diagnostics
  • 2.5.3 Important Role of Insurance for Diagnostics
• 2.6 Chromosomes, Genes and Epigenetics
  • 2.6.1 Chromosomes
  • 2.6.2 Genes
  • 2.6.3 Epigenetics
  • 2.6.4 Genetic Testing vs. Gene Sequencing
  • 2.6.5 Cost and Pricing Practice

3 Global Listing of Sequencer Installed Base - Location & Contacts

• 3.1 Notes to Installed Base Listing
• 3.2 Illumina Installed Base

4 Market Overview

• 4.1 Players in a Dynamic Market
  • 4.1.1 Academic Research Lab
  • 4.1.2 Diagnostic Test Developer
  • 4.1.3 Instrumentation Supplier
  • 4.1.4 Chemical/Reagent Supplier
  • 4.1.5 Pathology Supplier
  • 4.1.6 Independent Clinical Laboratory
  • 4.1.7 Public National/regional Laboratory
  • 4.1.8 Hospital Laboratory
  • 4.1.9 Physicians Office Lab (POLS)
  • 4.1.10 Audit Body
  • 4.1.11 Certification Body
• 4.2 Human Gene Sequencing - Markets, Examples and Discussion
  • 4.2.1 Inherited Disease - Not what it used to be
    • 4.2.1.1 Clinical and Research Lines Blur
    • 4.2.1.2 Genetic Counselling - Not so simple anymore
    • 4.2.1.3 The Genetic Blizzard - Issues of Access and Payment
  • 4.2.2 Newborn Screening - The Standard of Care
    • 4.2.2.1 Newborn Screening - Do Parents Want to Know?
  • 4.2.3 NIPT - We've Only Just Begun
    • 4.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS
    • 4.2.3.2 NIPT in the Future - Beyond Inherited Disease
  • 4.2.4 Oncology - Understanding Two Worlds
    • 4.2.4.1 The Tumor - A Sequence of Sequencing
    • 4.2.4.2 The Tumor - Biopsy and Liquid Biopsy
    • 4.2.4.3 The Human Genome - Predisposition and Prognosis
  • 4.2.5 Pharmacogenomics
    • 4.2.5.1 Sequencing Not the Only Player
    • 4.2.5.2 New Roles for Old Drugs - A Research Bonanza?
  • 4.2.6 Direct To Consumer - More Than Meets the Eye
    • 4.2.6.1 DTC - How Many Segments?
• 4.3 Industry Structure
  • 4.3.1 Hospital's Testing Share
  • 4.3.2 The Rise of the Sequencing Lab
  • 4.3.3 Sequencing as a Commodity
  • 4.3.4 Informatics
  • 4.3.5 Instrument Manufacturer Role
  • 4.3.6 Healthcare Industry Impacts - Still Struggling
  • 4.3.7 Can the Healthcare Industry Adapt?
  • 4.3.8 Genetic Counselling as an Industry
  • 4.3.9 Sequencing Adoption and Cannibalization

5 Market Trends

• 5.1 Factors Driving Growth
  • 5.1.1 New Diagnoses
  • 5.1.2 Wellness and Prevention
  • 5.1.3 Fertility Technology
  • 5.1.4 Cancer - Screening, Management and Monitoring
• 5.2 Factors Limiting Growth
  • 5.2.1 Increased Competition Lowers Price
  • 5.2.2 Lower Costs
  • 5.2.3 Healthcare Cost Concerns Curtail Growth
  • 5.2.4 Wellness has a downside
• 5.3 Sequencing Instrumentation
  • 5.3.1 Instrumentation Tenacity
  • 5.3.2 Declining Cost of Instruments Changes Industry Structure
  • 5.3.3 Long Reads - Further Segmentation
  • 5.3.4 Linked Reads
  • 5.3.5 New Sequencing Technologies

6 Human Gene Sequencing Recent Developments

• 6.1 Recent Developments - Importance and How to Use This Section
  • 6.1.1 Importance of These Developments
  • 6.1.2 How to Use This Section
• 6.2 Adaptive Biotechnologies MRD Testing Grows
• 6.3 GeneDx to Acquire Fabric Genomics
• 6.4 Inclusive Newborn Sequencing Shows Potential
• 6.5 Delve Bio: Delve Detect
• 6.6 Caris CDx Assay Approval
• 6.7 Ambry Genetics: ExomeReveal
• 6.8 WGS Improves Pediatric Cancer Care
• 6.9 Cancer genomes identify candidate driver genes
• 6.10 Genetic Dx a game changer
• 6.11 Nonacus Galeas Tumor
• 6.12 Lucence LiquidHallmark Assay Gets Coverage
• 6.13 Garvan Institute Gets Gramt to Develop Genomics Tests
• 6.14 Arima Genomics, Protean BioDiagnostics Launch Joint Venture
• 6.15 Geneseeq Nabs CE Marks for Cancer Test Kits
• 6.16 Viome Life Sciences Announces Gut Intelligence Test
• 6.17 Quest Diagnostics Announces Genetic Insights
• 6.18 Exact Sciences Releases Next-Gen Cologuard
• 6.19 BGI Genomics Forges Partnerships in Latin America
• 6.20 4bases Bets on NGS Diagnostics
• 6.21 Guardant Health Submits Colorectal Cancer Screening Test
• 6.22 Universal DX Eyeing Approval for Colorectal Cancer Screening Test
• 6.23 Natera Files Suit Against NeoGenomics
• 6.24 Genomics England to Sequence 100K Newborns
• 6.25 Novigenix Raises $14M for NGS based Liquid Biopsy
• 6.26 LetsGetChecked Launching New PGx Service
• 6.27 Qiagen, Neuron23 Partner for NGS Diagnostic
• 6.28 Harbinger Health Technology Focused On Oncogenesis
• 6.29 Delfi Diagnostics to Develop Early Detection Test
• 6.30 Dante Labs to Introduce WGS to Italian Healthcare System
• 6.31 Invitae Neurodevelopmental Disorders Testing Service
• 6.32 Thermo Fisher Obtains CE Mark for Ion Torrent Genexus
• 6.33 Myriad Genetics Launches Suite of Cancer Tests
• 6.34 Oncocyte and Thermo Fisher Strike Partnership Deal
• 6.35 Illumina Partners With Precision Medicine to Assess Liquid Biopsy
• 6.36 Sysmex Inostics Develops Ultra-Sensitive Liquid Biopsy
• 6.37 Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Testing
• 6.38 Strata Oncology Trial Supports NGS Assay
• 6.39 NYU Gets FDA Clearance for Sequencing Test
• 6.40 NeoGenomics to Acquire Inivata
• 6.41 OncoDNA, Institut Curie Partner on Liquid Biopsy Research
• 6.42 Cancer Heritability Gene Set Expanded
• 6.43 Whole-Genome Sequencing Could Replace Cytogenetics
• 6.44 Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays
• 6.45 Ancestry Shutters Health Offering
• 6.46 Genetron Health Targeting Early Cancer Detection
• 6.47 Pan-European Initiative to Build Tools for Sharing Genomic Data
• 6.48 UK Government Unveils New Genomic Healthcare Strategy
• 6.49 Foundation Medicine Liquid Biopsy Gets FDA Approval
• 6.50 American Heart Association Develops Genetic Testing Guidelines
• 6.51 Yourgene Health Gets CE Mark for Iona NIPT Test
• 6.52 NorthShore Looks to Expand Genomics Integration Into Primary Care
• 6.53 Germline Results From Tumor Sequencing Guides Precision Therapy
• 6.54 FDA Clears Cancer Genomic Profiling From Personal Genome Diagnostics
• 6.55 BillionToOne Closes $15M Series A Follow-on Round
• 6.56 Clinics to Integrate Genomics Into Primary Care

7 Profiles of Key Companies

• 7.1 10x Genomics, Inc.
• 7.2 23andME Inc.
• 7.3 Abbott Laboratories
• 7.4 AccuraGen Inc.
• 7.5 Adaptive Biotechnologies
• 7.6 Admera Health, LLC
• 7.7 Advanced Biological Laboratories
• 7.8 Agilent
• 7.9 Akonni Biosystems
• 7.10 Amoy Diagnostics Co., Ltd.
• 7.11 Ancestry.com LLC
• 7.12 Anchor Dx
• 7.13 Arrayit Corporation
• 7.14 ARUP Laboratories
• 7.15 Astrid Bio
• 7.16 Azenta
• 7.17 BaseClear
• 7.18 Baylor Miraca Genetics Laboratories
• 7.19 Beckman Coulter Diagnostics (Danaher)
• 7.20 Becton, Dickinson and Company
• 7.21 BGI Genomics Co. Ltd
• 7.22 Bioarray Genetics
• 7.23 BioBam
• 7.24 Biocept, Inc.
• 7.25 Biodesix Inc.
• 7.26 BioFluidica
• 7.27 BioGenex
• 7.28 Biolidics Ltd
• 7.29 bioMerieux Diagnostics
• 7.30 Bioneer Corporation
• 7.31 Bio-Rad Laboratories, Inc.
• 7.32 Bio-Techne
• 7.33 Burning Rock
• 7.34 C2i Genomics
• 7.35 Cantata Bio
• 7.36 CareDx
• 7.37 Caris Molecular Diagnostics
• 7.38 Celemics
• 7.39 CellMax Life
• 7.40 Centogene
• 7.41 Cepheid (Danaher)
• 7.42 Circulogene
• 7.43 Clearbridge Biomedics
• 7.44 Clinical Genomics
• 7.45 Color Genomics
• 7.46 Complete Genomics (MGI Tech)
• 7.47 CosmosID
• 7.48 Dante Labs
• 7.49 Datar Cancer Genetics Limited
• 7.50 Diasorin S.p.A.
• 7.51 Easy DNA
• 7.52 Element Biosciences
• 7.53 Epic Sciences
• 7.54 Epigenomics AG
• 7.55 Eurofins Scientific
• 7.56 Excellerate Bioscience
• 7.57 Fabric Genomics
• 7.58 Freenome
• 7.59 FUJIFILM Wako Diagnostics
• 7.60 Fujirebio
• 7.61 Fulgent Genetics
• 7.62 GE Global Research
• 7.63 Gene by Gene, Ltd.
• 7.64 Genedrive
• 7.65 GeneDx Holdings
• 7.66 GeneFirst Ltd.
• 7.67 GeneFluidics
• 7.68 Genetron Holdings
• 7.69 Genewiz
• 7.70 Genomics England
• 7.71 Genomics Personalized Health (GPH)
• 7.72 GenomOncology
• 7.73 Genzyme Corporation
• 7.74 Grifols
• 7.75 Guardant Health
• 7.76 Guardiome
• 7.77 Helix
• 7.78 Hologic
• 7.79 HTG Molecular Diagnostics
• 7.80 Human Longevity, Inc.
• 7.81 iCellate
• 7.82 Illumina
• 7.83 Incell Dx
• 7.84 Inivata
• 7.85 Invitae Corporation
• 7.86 Invivoscribe
• 7.87 Karius
• 7.88 Letsgetchecked
• 7.89 Lucence Health
• 7.90 Lunglife AI Inc
• 7.91 Macrogen
• 7.92 MDNA Life SCIENCES, Inc.
• 7.93 MDx Health
• 7.94 Medgenome
• 7.95 Meridian Bioscience
• 7.96 Mesa Laboratories, Inc.
• 7.97 Metabiomics Corp
• 7.98 miR Scientific
• 7.99 NantHealth, Inc.
• 7.100 Natera
• 7.101 Nebula Genomics
• 7.102 NeoGenomics
• 7.103 New England Biolabs, Inc.
• 7.104 NGeneBio
• 7.105 Norgen Biotek Corp.
• 7.106 Novogene
• 7.107 Omega Bioservices
• 7.108 Oncocyte
• 7.109 OncoDNA
• 7.110 OpGen
• 7.111 Origene Technologies
• 7.112 Oxford Nanopore Technologies
• 7.113 Pacific Biosciences
• 7.114 Panagene
• 7.115 PathoQuest S.A.
• 7.116 Personalis
• 7.117 PGDx (Labcorp)
• 7.118 Precipio
• 7.119 PrecisionMed
• 7.120 Predictive Oncology
• 7.121 Promega
• 7.122 Qiagen
• 7.123 QuantuMDx
• 7.124 Regeneron Pharmaceuticals
• 7.125 Revvity
• 7.126 Roche Diagnostics
• 7.127 Roswell Biotechnologies
• 7.128 Seegene
• 7.129 SeLux Diagnostics
• 7.130 Sequencing.com
• 7.131 Siemens Healthineers
• 7.132 simfo GmbH
• 7.133 Singlera Genomics Inc.
• 7.134 Singular Genomics
• 7.135 SkylineDx
• 7.136 Standard BioTools
• 7.137 Sysmex
• 7.138 Sysmex Inostics
• 7.139 Tempus Labs, Inc.
• 7.140 Thermo Fisher Scientific
• 7.141 Ultima Genomics
• 7.142 Unchained Labs
• 7.143 Variantyx
• 7.144 Vela Diagnostics
• 7.145 VolitionRX
• 7.146 Zymo Research Corp

8 The Global Market for Human Genome Sequencing

• 8.1 Global Market Overview by Country
  • 8.1.1 Table - Global Market by Country
  • 8.1.2 Chart - Global Market by Country
• 8.2 Global Market by Application - Overview
  • 8.2.1 Table - Global Market by Application
  • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
  • 8.2.3 Chart - Global Market by Application - Base Year
  • 8.2.4 Chart - Global Market by Application - Final Year
  • 8.2.5 Chart - Global Market by Application - Share by Year
  • 8.2.6 Chart - Global Market by Application - Segment Growth
• 8.3 Global Market by Technology - Overview
  • 8.3.1 Table - Global Market by Technology
  • 8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
  • 8.3.3 Chart - Global Market by Technology - Base Year
  • 8.3.4 Chart - Global Market by Technology - Final Year
  • 8.3.5 Chart - Global Market by Technology - Share by Year
  • 8.3.6 Chart - Global Market by Technology - Segment Growth
• 8.4 Global Market by Workflow - Overview
  • 8.4.1 Table - Global Market by Workflow
  • 8.4.2 Chart - Global Market by Workflow - Base/Final Year Comparison
  • 8.4.3 Chart - Global Market by Workflow - Base Year
  • 8.4.4 Chart - Global Market by Workflow - Final Year
  • 8.4.5 Chart - Global Market by Workflow - Share by Year
  • 8.4.6 Chart - Global Market by Workflow - Segment Growth
• 8.5 Global Market by Product - Overview
  • 8.5.1 Table - Global Market by Product
  • 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
  • 8.5.3 Chart - Global Market by Product - Base Year
  • 8.5.4 Chart - Global Market by Product - Final Year
  • 8.5.5 Chart - Global Market by Product - Share by Year
  • 8.5.6 Chart - Global Market by Product - Segment Growth

9 Market Sizes by Application

• 9.1 Hereditary Gene Sequencing Market
  • 9.1.1 Table - Hereditary by Country
  • 9.1.2 Chart - Hereditary Segment Growth
• 9.2 NIPT Gene Sequencing Market
  • 9.2.1 Table NIPT by Country
  • 9.2.2 Chart - NIPT Growth
• 9.3 Oncology Market
  • 9.3.1 Table - Oncology by Country
  • 9.3.2 Chart - Oncology Growth
• 9.4 Psychology Market
  • 9.4.1 Table - Psychology by Country
  • 9.4.2 Chart - Psychology Growth
• 9.5 WGES Gene Sequencing Market
  • 9.5.1 Table - WGES by Country
  • 9.5.2 Chart - WGES growth
• 9.6 Pharmacogenomics Market
  • 9.6.1 Table Pharmacogenomics by Country
  • 9.6.2 Chart - Pharmacogenomics Growth
• 9.7 DTC Gene Sequencing Market
  • 9.7.1 Table - DTC by Country
  • 9.7.2 Chart - DTC Growth
• 9.8 Research Gene Sequencing Market
  • 9.8.1 Table - Research by Country
  • 9.8.2 Chart - Research Growth
• 9.9 Other Application Market
  • 9.9.1 Table - Other Application by Country
  • 9.9.2 Chart - Other Application growth

10 Market Sizes by Technology

• 10.1 Sanger Sequencing Market
  • 10.1.1 Table - Sanger by Country
  • 10.1.2 Chart - Sanger Segment Growth
• 10.2 NGS/2G Market
  • 10.2.1 Table NGS/2G by Country
  • 10.2.2 Chart - NGS/2G Growth
• 10.3 3G/Long Market
  • 10.3.1 Table - 3G/Long by Country
  • 10.3.2 Chart - 3G/Long Growth
• 10.4 Other Technology Market
  • 10.4.1 Table - Other Technology by Country
  • 10.4.2 Chart - Other Technology Growth

11 Market Sizes by Workflow

• 11.1 Sequencing Market
  • 11.1.1 Table - Sequencing by Country
  • 11.1.2 Chart - Sequencing Segment Growth
• 11.2 Sample Prep Market
  • 11.2.1 Table Sample Prep by Country
  • 11.2.2 Chart - Sample Prep Growth
• 11.3 Analysis Market
  • 11.3.1 Table - Analysis by Country
  • 11.3.2 Chart - Analysis Growth

12 Market Sizes by Product

• 12.1 Instruments Market
  • 12.1.1 Table - Instruments by Country
  • 12.1.2 Chart - Instruments Segment Growth
• 12.2 Consumables Market
  • 12.2.1 Table Consumables by Country
  • 12.2.2 Chart - Consumables Growth
• 12.3 Software & Services Market
  • 12.3.1 Table - Software & Services by Country
  • 12.3.2 Chart - Software & Services Growth

13 Vision of the Future of Human Gene Sequencing

14 Appendices

• 14.1 Growth of Approved IVD Test Menu
• 14.2 Growth of Approved Average IVD Test Fee
• 14.3 The Most Used IVD Assays
• 14.4 The Highest Grossing Assays
• 14.5 Laboratory Fees Schedule
• 14.6 The Whole Genome Sequence of SARS-CoV-2

Table of Tables

• Table 1 The Base Pairs
• Table 2 Most Common Traditional Genetic Disorders
• Table 3 The Base Pairs
• Table 4 List of GLOBAL SEQUENCING LOCATIONS
• Table 5 Market Players by Type
• Table 6 The Different Markets for Human Gene Sequencing
• Table 7 DTC Sub Segments
• Table 8 The Factors Driving Growth
• Table 9 Factors Limiting Growth
• Table 10 Six New Sequencing Technologies
• Table 11 - Global Market by Region
• Table 12 Global Market by Application
• Table 13 Global Market by Technology
• Table 14 Global Market by Workflow
• Table 15 Global Market by Product
• Table 16 Hereditary Segment by Country
• Table 17 NIPT Segment by Country
• Table 18 Oncology Segment by Country
• Table 19 Psychology Segment by Country
• Table 20 WGES Segment by Country
• Table 21 Pharmacogenomics Segment by Country
• Table 22 DTC Segment by Country
• Table 23 Research Segment by Country
• Table 24 Other Application Segment by Country
• Table 25 Sanger Segment by Country
• Table 26 NGS/2G Segment by Country
• Table 27 3G/Long Segment by Country
• Table 28 Other Technology by Country
• Table 29 Sequencing Segment by Country
• Table 30 Sample Prep Segment by Country
• Table 31 Analysis Segment by Country
• Table 32 Instruments Segment by Country
• Table 33 Consumables Segment by Country
• Table 34 Software & Services Segment by Country
• Table 35 The Most Common Assays
• Table 36 Largest Revenue Assays
• Table 37 Clinical Lab Fee Schedule

Table of Figures

• Figure 1 Global Healthcare Spending
• Figure 2 The Lab Test Pie
• Figure 3 DNA Strands and Chromosomes
• Figure 4 Karyogram of Human Chromosomes
• Figure 5 Size of Various Genomes
• Figure 6 Global Illumina Installed Base Map
• Figure 7 The Road to Diagnostics
• Figure 8 TruSight Germline Panel
• Figure 9 Historical Cost of Gene Sequencing
• Figure 10 - Cost To Sequence a Human Genome
• Figure 11 Base Year Country Market Share Chart
• Figure 12 Global Market by Application - Base vs. Final Year
• Figure 13 Global Market by Application Base Year
• Figure 14 Global Market by Application Final Year
• Figure 15 Application Type Share by Year
• Figure 16 by Application Segment Growth
• Figure 17 Global Market by Technology - Base vs. Final Year
• Figure 18 Global Market by Technology Base Year
• Figure 19 Global Market by Technology Final Year
• Figure 20 Technology Type Share by Year
• Figure 21 by Technology Segment Growth
• Figure 22 Global Market by Workflow - Base vs. Final Year
• Figure 23 Global Market by Workflow Base Year
• Figure 24 Global Market by Workflow Final Year
• Figure 25 Workflow Type Share by Year
• Figure 26 by Workflow Segment Growth
• Figure 27 Global Market by Product - Base vs. Final Year
• Figure 28 Global Market by Product Base Year
• Figure 29 Global Market by Product Final Year
• Figure 30 Product Type Share by Year
• Figure 31 by Product Segment Growth
• Figure 32 Hereditary vs. Total Market Growth
• Figure 33 NIPT vs. Total Market Growth
• Figure 34 Oncology vs. Total Market Growth
• Figure 35 Psychology vs. Total Market Growth
• Figure 36 WGES vs. Total Market Growth
• Figure 37 Pharmacogenomics vs. Total Market Growth
• Figure 38 DTC vs. Total Market Growth
• Figure 39 Research vs. Total Market Growth
• Figure 40 Other Application vs. Total Market Growth
• Figure 41 Sanger vs. Total Market Growth
• Figure 42 NGS/2G vs. Total Market Growth
• Figure 43 3G/Long vs. Total Market Growth
• Figure 44 Other Technology vs. Total Market Growth
• Figure 45 Sequencing vs. Total Market Growth
• Figure 46 Sample Prep vs. Total Market Growth
• Figure 47 Analysis vs. Total Market Growth
• Figure 48 Instruments vs. Total Market Growth
• Figure 49 Consumables vs. Total Market Growth
• Figure 50 Software & Services vs. Total Market Growth
• Figure 51 IVD Test Menu Growth
• Figure 52 IVD Test Average Fees - A Ten Year View